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Abstract
Background—Growth promoting signals from the epicardium are essential for driving
myocardial proliferation during embryogenesis. In adults, these signals become reactivated
following injury and promote angiogenesis and myocardial repair. Therefore, identification of
such paracrine factors could lead to novel therapeutic strategies. The multi-functional peptide
adrenomedullin (Adm = gene, AM = protein) is required for normal heart development. Moreover,
elevated plasma AM following myocardial infarction offers beneficial cardioprotection and serves
as a powerful diagnostic and prognostic indication of disease severity.
Results—Here, we developed a new model of Adm overexpression by stabilizing the Adm
mRNA through gene-targeted replacement of the endogenous 3′ untranslated region. As expected,
Admhi/hi mice express three-times more AM than controls in multiple tissues, including the heart.
Despite normal blood pressures, Admhi/hi mice unexpectedly showed significantly enlarged hearts
due to increased cardiac hyperplasia during development. The targeting vector was designed to
allow for reversion to wild-type levels by means of Cre-mediated modification. Using this
approach, we demonstrate that AM derived from the epicardium, but not the myocardium or
cardiac fibroblast, is responsible for driving cardiomyocyte hyperplasia.
Conclusions—AM is produced by the epicardium and drives myocyte proliferation during
development, thus representing a novel and clinically relevant factor potentially related to
mechanisms of cardiac repair after injury.
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Introduction
Recently, many exciting connections between factors that regulate myocardial development
and those that are elevated during myocardial injury have been appreciated (Degenhardt et
al., 2013). Central to these connections are the unique roles of the epicardium during
embryogenesis and the newly emerging concept that the epicardium becomes reactivated—
re-expressing fetal genes—during disease processes (Gittenberger-de Groot et al., 2012). For
example, studies in zebrafish and mice have shown that the epicardium is required for
maintenance of myocardial proliferation during embryogenesis through several growth
promoting signaling pathways including Raldh2, Wt-1, IGF, FGF, and β1 integrin (Chen et
al., 2002; Lavine et al., 2005; Ieda et al., 2009; Guadix et al., 2011; Kikuchi et al., 2011).
During cardiac injury, many of these same growth promoting factors become stimulated
such that the potential of the epicardium to contribute to heart regeneration and repair is
restored from its normally adult quiescent state (Huang et al., 2012; van Wijk et al., 2012).
Several recent studies have begun to elucidate the pleiotropic roles for epicardial-derived
cells (EPDCs) in the formation of numerous cardiac cell types, including coronary
endothelial and smooth muscle cells, cardiac fibroblasts, heart valves and perhaps even
cardiomyocytes (Gittenberger-de Groot et al., 2012; Degenhardt et al., 2013). However, it is
also evident that an important function of the epicardium is to secrete paracrine factors that
promote angiogenesis, myocardial regeneration and cardiac fibroblast proliferation (Smart et
al., 2011; Duan et al., 2012). Therefore identifying new factors that exhibit these dual roles
of supporting both embryonic and injured heart growth is a desirable and clinically
promising area of research.
In this study, we find that adrenomedullin peptide, secreted from the epicardium, is a potent
regulator of cardiomyocyte proliferation during embryogenesis. Since the discovery of
adrenomedullin (protein = AM, gene = Adm) in 1993 (Kitamura et al., 1993), many diverse
biological functions have been described for this small circulating peptide during
development, normal physiology and disease (Caron and Smithies, 2002; Karpinich et al.,
2011). We, and others, have previously shown that genetic deletion of the highly conserved
Adm gene in mice causes embryonic lethality at mid-gestation (Caron and Smithies, 2001;
Shindo et al., 2001; Shimosawa et al., 2002). The most prominent phenotype of Adm−/−
embryos is their extreme hydrops fetalis, or interstitial edema, which we have attributed to a
marked arrest of lymphatic endothelial cell proliferation and lymphangiogenesis at mid-
gestation (Fritz-Six et al., 2008). However, the expression of Adm, although enriched in
lymphatic endothelial cells, is not restricted. Indeed, the earliest and most robust expression
of Adm can be observed in the heart at around E8.0 (Montuenga et al., 1997, 1998; Caron
and Smithies, 2001). Consequently, we found that Adm−/− mice also have small hearts
characterized by enhanced trabeculation and a thin compact zone (Caron and Smithies,
2001). Furthermore, loss of either the receptor for AM, calcitonin receptor-like receptor
(Calcrl) (Dackor et al., 2006), or the receptor modifying protein Ramp2 (Fritz-Six et al.,
2008) results in a phenocopy of the Adm−/− phenotype. Taken together, the highly conserved
and robust cardiac phenotypes of mice with genetic deletion of AM signaling components
demonstrates the essential function of AM in promoting embryonic heart development.
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A multitude of clinical studies have also shown that circulating levels of AM are elevated
two- to three-fold above basal levels during a variety of human disease conditions
(Karpinich et al., 2011). Recently, the robust surge in plasma AM levels during
cardiovascular disease is being used as a clinical diagnostic tool. The pro-hormone form of
AM, mid regional pro-AM (MRpro-AM), is a highly effective clinical biomarker of patient
prognosis following heart attack, providing greater sensitivity than traditional biomarkers
such as atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) (Dhillon et al.,
2010; Maisel et al., 2010, 2011). In addition, AM also offers protection from cardiovascular
disease. Several studies using mice haploinsufficient for Adm, have clearly demonstrated an
exacerbation of cardiovascular disease with a reduction in basal levels of AM (Shimosawa et
al., 2002; Caron et al., 2007), highlighting the importance of circulating AM in controlling
the extent of damage. Additionally, animal studies examining the impact of AM infusion on
cardiovascular disease progression have revealed a protective effect of AM on disease
progression (Rademaker et al., 1997; Nishikimi et al., 2003b). Furthermore, a limited
number of studies performed in human patients have demonstrated that infusion of AM after
a cardiovascular incident is associated with a reduction in the degree of damage (Nagaya et
al., 2000; Nishikimi et al., 2009; Kataoka et al., 2010). However, because these studies have
relied on the infusion of AM, it remains unclear whether the physiological three-fold
increase of circulating AM during cardiovascular disease has any direct or protective
implications.
Therefore, we sought to develop a mouse model that recapitulates the plasma elevation of
AM observed during human disease as a useful tool for elucidating the precise functions of
AM in cardioprotection. Herein, we describe the successful generation of a novel mouse
model of Adm overexpression that was intentionally designed to conserve the endogenous
promoter regulatory elements of the gene, with the added capability of reversing the
overexpression by Cre-LoxP strategies. Surprisingly, we discovered that these animals have
enlarged hearts due to cardiac hyperplasia during development, a phenotype that was
reversed when high AM levels from the epicardium were genetically restored to basal levels.
Results
Transcriptional and Translational Up-Regulation of Adm Expression in Admhi/hi Mice
We recently described the generation of the Admhi/hi mice by gene targeting techniques
which allowed for the stabilization of the Adm mRNA half-life by the bovine growth
hormone 3′ untranslated region (UTR) (Li et al., 2013). Previous in vitro studies predicted
that this modification would stabilize the mRNA transcript of Adm by approximately 3.5-
fold compared with the native transcript, while still allowing for endogenous regulation of
Adm gene expression by its native 5′UTR promoter region (Kakoki et al., 2004). Here we
show that Adm mRNA transcript levels, as measured by quantitative reverse transcriptase-
polymerase chain reaction (qRT-PCR), were statistically increased by approximately 3- to
15-fold in Admhi/hi mice compared with wild-type control animals in ten different tissues at
4 months of age (Fig. 1A). Moreover, a radioimmunoassay for total AM peptide levels
revealed a statistically significant ∼three-fold increase in AM peptide levels from kidney
and lung extracts (Fig. 1B). Analysis of circulating AM in the blood plasma of 4-month-old
Wetzel-Strong et al. Page 3
Dev Dyn. Author manuscript; available in PMC 2015 February 01.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
animals by a fluorescent EIA method also showed a significant two- to three-fold increase in
Admhi/hi animals compared with wild-type littermates (Fig. 1C). Thus, the 3′UTR gene
targeting approach successfully recapitulated the increases in Adm mRNA and peptide
expression at a level that is comparable to that observed in human patients with
cardiovascular disease and myocardial infarction.
Enhanced Adm Expression in Developing Heart of Admhi/hi Mice
Previous studies have shown the developing embryonic mouse heart expresses Adm as early
as E8.0 and this expression persists throughout development and into adulthood (Montuenga
et al., 1997; Caron and Smithies, 2001). Using immunohistochemistry, we find that
endogenous levels of AM peptide expression are localized to the epicardium, with very low
levels of expression in the compact zone and trabeculae at embryonic day (E) 13.5 (Fig.
2A,C). Similarly, Admhi/hi mice showed this same spatiotemporal pattern, but as expected,
using semiquantitative imaging, we observed a robust and marked increase in AM
expression from the epicardium and trabeculae compared with wild-type animals (Fig.
2B,D). By assessing the integrated density of AM at the epicardium, we confirmed that
Admhi/hi embryos express higher levels of AM compared with wild-type controls (Fig. 2E).
We also confirmed that AM is expressed in the epicardium by staining adjacent sections for
AM and cytokeratin (Fig. 2F,G), which has been previously characterized as a marker of the
epicardium (Viragh et al., 1993; Pennisi et al., 2003). This staining clearly demonstrates that
AM is predominantly and robustly expressed in the epicardium, and to a much lesser extent
in the myocardium. Another prominent feature of Admhi/hi hearts that can be appreciated
from these images is the apparently larger size of the ventricle compared with Adm+/+ hearts
viewed at the same magnification (compare Fig. 2A,B).
Admhi/hi Mice Have Enlarged, Hyperplastic Hearts
Unexpectedly, we discovered that 2-month-old Admhi/hi mice had remarkably and visibly
enlarged hearts compared with wild-type controls (Fig. 3A). Heart weight to body weight
(HW:BW) ratios (Fig. 3B), as well as heart weight to tibia length (HW:TL) ratios (Fig. 3C)
were significantly increased compared with wild-type control mice. Individual chamber
dissections revealed that both ventricles and atria of Admhi/hi hearts were significantly
enlarged compared with those of littermates (Fig. 3D).
Because either hypertrophic or hyperplastic mechanisms could contribute to enlargement of
the heart, we used histological techniques to evaluate cardiomyocyte size and density. We
found no difference in the cardiomyocyte cross-sectional area between wild-type and
Admhi/hi animals, suggesting that the enlarged hearts of Admhi/hi animals were not
hypertrophic (Fig. 4A). This conclusion was further supported by quantitation of
cardiomyocyte cellular density from wheat germ agglutinin stained sections, which also
revealed no difference in cellular myocyte density between Admhi/hi animals and wild-type
controls (Fig. 4B,C). Additionally, qRT-PCR analysis of the pro-hypertrophic genes, Anp
and Bnp, showed no significant differences between wild-type and Admhi/hi animals (Anp
expression = 1.20 ± 0.3 vs. 1.87 ± 0.3; Bnp expression = 1.07 ± 0.2 vs. 1.83 ± 0.4 for wild-
type and Admhi/hi, respectively), further confirming that Admhi/hi hearts are not
hypertrophied. Finally, using isolectin staining, we also found no significant differences in
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vascular morphology or density between Admhi/hi animals and control animals (Fig. 4B,C).
Based on these analyses, it was evident that the Admhi/hi hearts were enlarged due to
hyperplasia, not hypertrophy, a conclusion that is further supported by the fact that Admhi/hi
mice do not have elevated blood pressures (Fig. 4D).
Because Adm expression is prominently enriched in the heart during embryogenesis (Fig. 2),
we performed bromodeoxyuridine (BrdU) incorporation studies to quantitate the number of
proliferating cells in the hearts of wild-type and Admhi/hi embryos. We assessed proliferation
at six different time points of embryonic development, and importantly found that Admhi/hi
embryos always had more BrdU-positive cells per normalized field compared with wild-
type, with significant differences in five out of six time points (Fig. 5A,B). From this
analysis, it is also interesting to note that the shape of the proliferation curve for Admhi/hi
animals recapitulates the shape of the curve exhibited by wild-type animals (see Fig. 5B),
indicating that Admhi/hi hearts are still appropriately responding to signals responsible for
regulating proliferation rates during development.
To further confirm this developmental hyperplasia, we stained E12.5 hearts with phospho-
Histone H3 (Fig. 5C), a less prevalent proliferation marker, and the cardiomyocyte marker,
cardiac troponin T (cTnT). Consistent with the BrdU staining, we found a statistically
significant increase in the level of phospho-Histone H3 labeling in Admhi/hi hearts compared
with wild-type littermates (Fig. 5C). Moreover, by co-staining with cTnT, we could easily
identify the phospho-Histone H3-positive cells as cardiomyocytes, by identifying phospho-
H3-positive nuclei that were surrounded by cTnT signal, as indicated by the asterisks in the
×40 images in Figure 5C. Finally, we also compared the overall heart size of wild-type and
Admhi/hi animals at the level of the ventricular valves at E15.5 and as expected, the enhanced
levels of proliferation in Admhi/hi hearts resulted in a visible enlargement in the heart size of
Admhi/hi embryos (Fig. 5D).
High AM Drives the Cardiomyocyte Cell Cycle
Cyclins and cyclin dependent kinases are critical for maintaining normal cardiomyocyte
proliferation during development. Therefore, we further confirmed the accelerated degree of
proliferation in Admhi/hi hearts by assessing protein levels of cyclin B1 and cyclin D1 by
Western blotting of postnatal day 1 heart lysates. Our choice of postnatal day 1 tissue for
these assays was based on the need to isolate sufficient amounts of protein for Western
analysis but, furthermore, allowed us to interrogate whether the hyperplasia of Admhi/hi
animals persists through the end of the proliferative phase of cardiac development. This
analysis revealed a significant elevation of both cyclin B1 and cyclin D1 protein in the hearts
of Admhi/hi pups compared with wild-type (Fig. 5E), even during the early postnatal period.
As in the late stages of embryonic heart development, the proliferation rates in Admhi/hi
hearts are modestly, but significantly elevated compared with wild-type animals, further
highlighting the responsiveness of proliferating cardiomyocytes in Admhi/hi hearts to
intrinsic regulators of the cell cycle.
To determine whether cells in Admhi/hi hearts do indeed exit the cell cycle in a manner
comparable to wild-type animals, we also assessed proliferation in the hearts of 6-month-old
adult wild-type and Admhi/hi animals by Ki67 staining. This analysis revealed that levels of
Wetzel-Strong et al. Page 5
Dev Dyn. Author manuscript; available in PMC 2015 February 01.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
proliferation are very low in the hearts of both wild-type and Admhi/hi groups, and we found
no significant difference in the degree of proliferation (data not show), clearly demonstrating
that the hyperplasia of Admhi/hi animals is limited to the developmental period.
We sought to further confirm our in vivo data demonstrating that AM can act directly on
cardiomyocytes to drive the cell cycle by treating HL-1 cells, a cardiomyocyte cell line, with
AM peptide. We chose to use the HL-1 cell line because previous studies have demonstrated
that these cells retain many properties of adult cardiomyocytes in culture, including:
cardiomyocyte-specific currents, gene expression profiles resembling adult cardiomyocytes,
and the presence of cardiomyocyte-specific structures, such as intercalated discs (Claycomb
et al., 1998). Additionally, HL-1 cells have the ability to proliferate in culture without losing
these cardiomyocyte characteristics (Claycomb et al., 1998), unlike isolated neonatal
cardiomyocytes. Thus, we treated the HL-1 cell line with 1nM AM or vehicle in serum-free
media and measured cell counts. After 72-hr of treatment, there were significantly more
HL-1 cells in the AM-treated conditions compared with vehicle-treated cells (Fig. 5F),
indicating that AM can directly drive the proliferation of cardiomyocytes. These data, along
with our in vivo data, clearly demonstrate first, that AM can act directly on cells to drive
proliferation, and second, that elevated AM promotes cardiac hyperplasia.
Reversion of the Admhi Allele to Basal Levels Reverses the Cardiac Hyperplasia
The design of our targeting vector intentionally included loxP sites flanking the bGH 3′UTR
stabilizing element to allow for tissue- and time-dependent reversion of high Adm levels
back to wild-type levels (Fig. 6A). To confirm that this approach was effective, we crossed
the Admhi/+ mice to the CMV-Cre line (Schwenk et al., 1995) to generate mice with a wild-
type Adm allele, as well as a modified Admhi allele, referred to as Adm3′Δ. Adm3′Δ
heterozygous mice were then intercrossed, at which point the CMV-Cre transgene was
selected against to generate homozygous Adm3′Δ/3′Δ mice. By qRT-PCR, we found that
Adm3′Δ/3′Δ mice express Adm at levels comparable to wild-type littermates (Fig. 6B),
confirming that removal of the stabilizing bGH 3′UTR element results in a reversion of Adm
levels to near basal levels.
Importantly, this genetic modification also reversed the cardiac hyperplasia phenotype of
Admhi/hi mice. At 2 months of age, we assessed the HW:BW ratios of wild-type, Admhi/hi,
and Adm3′Δ/3′Δ mice. We found that Adm3′Δ/3′Δ mice had HW:BW ratios that were
significantly smaller than Admhi/hi mice, and indistinguishable from those of wild-type mice
(Fig. 6C). Together, these data demonstrate the feasibility of genetically reversing the Admhi
allele to normal levels, which is also associated with a reversal of the Admhi/hi cardiac
hyperplasia phenotype.
AM Derived From Wt1-Positive Cells Promotes Enhanced Heart Size of Admhi/hi Mice
Our next goal was to use this genetic approach to identify the cellular source of AM that
drives the observed cardiac hyperplasia during development. After confirming that we
would be able to detect a decrease in HW:BW with a global reduction in Adm expression,
we proceeded to cross the Admhi/hi mice to several different Cre mouse lines to assess the
contribution of Adm from different cell types within the heart with respect to organ growth.
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We began by assessing the contribution of cardiomyocyte-derived AM because the
myocardium can release growth factors to regulate heart growth and development (Vega-
Hernandez et al., 2011). Therefore, we crossed the Admhi/hi mice to two independent
cardiomyocyte-specific Cre lines, the Nkx2.5-Cre (Moses et al., 2001) and αMHC-Cre
(Agah et al., 1997) lines. At 2 months of age, we found there was no significant difference in
the HW:BW ratio of Admhi/hi and Nkx2.5-Cre+: Adm3′Δ/3′Δ mice (Fig. 7A). Additionally,
we found no difference in the HW:BW ratio of Admhi/hi and αMHC-Cre+: Adm3′Δ/3′Δ mice
(data not shown). Together, these two independent cardiomyocyte-specific Cre lines clearly
indicate that cardiomyocytes are not the cellular source of AM driving the heart growth
during development.
Tomoda et al. found that the non-myocyte fraction of the rat heart expressed approximately
2.5 times more Adm than the myocyte fraction, suggesting that cardiac fibroblasts are a
major source of AM in the heart (Tomoda et al., 2001). Therefore, we crossed the Admhi/hi
mice to the Fsp-Cre (Bhowmick et al., 2004) mouse line to reduce Adm to wild-type levels
in fibroblasts. Once again, we found there was no significant difference between Admhi/hi
and Fsp-Cre+: Adm3′Δ/3′Δ mice at 2 months of age (Fig. 7B), suggesting that cardiac
fibroblasts are not a major producer of AM during embryonic heart development.
Finally, we sought to determine whether AM derived from the epicardium contributed
significantly to heart development because many studies have described the importance of
the epicardium in secreting paracrine growth factors that regulate heart growth (Lavine et
al., 2005; Lu et al., 2008; Li et al., 2011), and our data demonstrate that the epicardium is a
major source of Adm expression during embryogenesis (Fig. 2). By crossing the
Wt1GFPCre/+ (Zhou et al., 2008) mice to the Admhi/hi line, we were able to generate mice
with reduced Adm in the epicardium (Fig. 7D). In this case, we discovered that Wt1GFPCre/+:
Adm3′Δ/3′Δ mice had HW:BW ratios that were significantly lower that Admhi/hi animals, and
not significantly different from wild-type animals (Fig. 7C). We also stained adjacent
sections of the left ventricle from these animals for cytokeratin, to mark the epicardium, and
AM (Fig. 7D). We found that AM colocalized with cytokeratin expression in the
epicardium, further confirming the expression and contribution of epicardial-derived AM in
heart development. These images also reveal that AM expression of Wt1GFPCre/+:
Adm3′Δ/3′Δ mice is reduced in the epicardium compared with Admhi/hi animals (Fig. 7E) and
is similar to wild-type littermates, thereby verifying that we successfully reduced AM
expression in the epicardium of these animals, resulting in the normalization of heart size.
Finally, to further corroborate these findings, we assessed Adm gene expression levels using
RNA extracted from 2-month-old left ventricle samples from Admhi/hi and
Wt1GFPCre/+:Adm3′Δ/3′Δ mice. This experiment revealed that Adm expression levels are
significantly reduced to near baseline values in Wt1GFPCre/+:Adm3′Δ/3′Δ mice compared
with Admhi/hi animals (Fig. 7F). Because Cre recombinase is expressed specifically in the
pro-epicardium and epicardium in the Wt1GFPCre/+ line (Zhou et al., 2008), we concluded
that a reduction in Adm expression level is due to a normalization of Adm expression levels
specifically in the epicardium. Although Adm expression levels were still elevated over
wild-type levels in Wt1GFPCre/+:Adm3′Δ/3′Δ animals, it is important to recognize that this
difference can be attributed to the fact that other cell types in the heart, including
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cardiomyocytes and fibroblasts, are still overexpressing Adm. Because we have
demonstrated that a reduction of Adm levels in cardiomyocytes and fibroblasts fails to affect
the HW:BW ratios (Fig. 7A and 7B), these data indicate that the epicardium is a major
source of Adm that promotes cardiac hyperplasia in the Admhi/hi line.
Discussion
With this unique gene targeted mouse model, we have identified AM as a powerful regulator
of cardiac growth during embryogenesis. Importantly, we have been able to demonstrate that
AM secreted from epicardial cells is important for driving the cardiomyocyte cell cycle and
promoting enlargement of the heart during embryogenesis. Considering the numerous and
high profile clinical studies which link elevated plasma AM levels following myocardial
infarction with both disease severity and cardioprotection, we consider that AM fulfills the
characteristics of a newly recognized epicardial-derived growth factor that may play
important roles in cardiac repair and regeneration.
Most importantly, the pharmacological targeting of AM signaling is readily achievable
through small molecule agonists and antagonists capable of binding to the unique interface
formed between the AM receptor, calcitonin receptor-like receptor and receptor activity
modifying protein (RAMP) 2 (Archbold et al., 2011). Indeed this receptor- RAMP paradigm
is already being exploited by the pharmaceutical industry for the treatment of migraine pain
associated with CGRP signaling (Doods et al., 2007; Salvatore et al., 2010). Therefore,
while the delivery of AM peptide has some limitations as a treatment strategy for
myocardial infarction, activation of AM signaling through its unique G protein-coupled
receptor paradigm is attainable.
In the literature, a limited number of mouse models have been reported that display cardiac
hyperplasia (Chaudhry et al., 2004; Kerkela et al., 2008; Trivedi et al., 2008; Qiu et al.,
2010; Heallen et al., 2011; Phillips et al., 2011). Many of these mutant animals die during
the late embryonic development or the early postnatal period (Kerkela et al., 2008; Qiu et
al., 2010; Heallen et al., 2011; Phillips et al., 2011), which contrasts with this Admhi/hi
model, which survives into adulthood. This difference can, perhaps, be attributed to the
presence of additional cardiac defects in some lines or differences in how the heart is
enlarged. For example, many of these mouse lines display other cardiac abnormalities in
addition to cardiomyocyte hyperplasia, including: ventricular septal defects (Kerkela et al.,
2008; Heallen et al., 2011; Phillips et al., 2011), double outlet right ventricles (Kerkela et al.,
2008), and dilated atria (Qiu et al., 2010; Phillips et al., 2011). The Admhi/hi mice do not
display additional cardiac defects, which potentially explains why these mice are viable.
Moreover, several of the other reported mouse lines displaying cardiac hyperplasia display a
reduction in the luminal space of the ventricle due to a robust increase in the space occupied
by the trabeculi as well as a drastic increase in the thickness of the compact layer (Kerkela et
al., 2008; Qiu et al., 2010; Heallen et al., 2011; Phillips et al., 2011). Because the degree of
trabeculation between wild-type and Admhi/hi animals appears similar, the lumens of the
Admhi/hi mice remain unobstructed, allowing for normal heart function and viability of the
mice.
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We found that a reduction of Adm in the epicardium through the use of the Wt1GFPCre/+
mouse line resulted in a reversion of the HW:BW ratio back to wild-type levels, indicating
that the cardiac hyperplasia phenotype of the Admhi/hi mice is caused by enhanced
epicardial-derived AM. Some studies have indicated that Wt1 is expressed in a subset of
cardiomyocytes during embryonic development (Rudat and Kispert, 2012), and therefore,
the Wt1GFPCre/+ line may promote recombination directly in the cardiomyocytes.
Additionally, other groups have suggested that epicardial cells may differentiate into
cardiomyocytes (Cai et al., 2008; Zhou et al., 2008), and thus the recombined genes from the
cross to the Wt1GFPCre/+ line may be transmitted to the cardiomyocyte lineage. Therefore, it
is possible that additional recombination in cardiomyocytes through one of these two
mechanisms is contributing to the reduction of the HW:BW ratio in
Wt1GFPCre/+:Adm3′Δ/3′Δ mice. However, our data from two independent cardiomyocyte-
specific Cre lines showing no reduction in HW:BW with reduced levels of AM expression
in cardiomyocytes suggests that the contribution of cardiomyocyte-derived AM to the
developmental hyperplasia observed in the Admhi/hi line is minimal.
Our conclusion that the epicardium is a major contributor of AM during heart development
is further supported by the similarities between the heart phenotype of Adm−/− mice (Caron
and Smithies, 2001) and animals with a disrupted epicardium (Kreidberg et al., 1993; Kwee
et al., 1995; Pennisi et al., 2003; Li et al., 2011). Specifically, one characteristic of animals
lacking an epicardium or with disrupted growth factor secretion from the epicardium is a
thin compact zone (Kreidberg et al., 1993; Kwee et al., 1995; Pennisi et al., 2003; Li et al.,
2011), which was also observed in the Adm−/− mice (Caron and Smithies, 2001). Although
Adm−/− animals do not exhibit other cardiac defects that are sometimes described in other
models with epicardial alterations, it is possible that AM acts independently or through
different growth factors than those investigated to date. Additionally, it is possible that AM
may play a role in the endocardium, as Adm−/− embryos also have abnormal trabeculation
compared with wild-type littermates (Caron and Smithies, 2001), and the endocardium has
been implicated in the regulation of trabecular development (Gassmann et al., 1995; Lee et
al., 1995; Meyer and Birchmeier, 1995; Stainier et al., 1995; Grego-Bessa et al., 2007).
However, because the majority of the proliferation we observed in the hearts of Admhi/hi
hearts was localized to the compact zone and septum (see Fig. 5C) and the development of
these areas is largely regulated by the epicardium (Gittenberger-de Groot et al., 2000; Sucov
et al., 2009), it seems likely that endocardial-derived AM contributes minimally to the
observed cardiac hyperplasia.
Our current study does not excluded the possibility that AM may interact with other growth
factors to promote cardiac hyperplasia in Admhi/hi animals. To date, several epicardial-
derived factors critical to compact zone proliferation have been identified. These factors
include several members of the fibroblast growth factor (FGF) family (Lavine et al., 2005),
members of the insulin growth factor (IGF) signaling cascade (Li et al., 2011), as well as
retinoic acid (RA) (Chen et al., 1998, 2002; Stuckmann et al., 2003; Merki et al., 2005) and
erythropoietin (Epo) (Wu et al., 1999; Stuckmann et al., 2003). Presently, it remains unclear
whether any interaction exists between AM and these factors in the heart to promote the
cardiac hyperplasia observed in Admhi/hi animals. Similar to AM, the FGFs and their
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corresponding receptors are widely expressed throughout the body during development and
play an important role in regulating cellular growth in many organ systems (Lea et al.,
2009). Although there have been very few studies investigating any relationship between
AM and the FGFs, one recent study found that transgenic overexpression of FGF18 in the
lung during the early postnatal development period promoted an increase in Adm expression
(Franco-Montoya et al., 2011), indicating the potential for crosstalk between these two
signaling pathways; however, it is unknown whether a similar paradigm exists in the heart
during embryonic development. Another potential mechanism by which the Adm signaling
pathway may interact with other epicardial-derived signals is through the transactivation of
FGF and IGF receptors. Guidolin et al. (2008) have reported that AM may transactivate
VEGFR2 to promote angiogenesis in human vascular endothelial cells. Specifically, they
found that the angiogenic properties of AM were dependent on the tyrosine kinase domain
of the VEGFR2 receptor, (Guidolin et al., 2008) which suggests that other receptor tyrosine
kinases, such as the FGF and IGF receptors, may be subject to transactivation by AM
signaling. Furthermore, Cornish et al. (Cornish et al., 2004) found that AM-induced
proliferation of osteoblasts was inhibited with the loss of IGF-1R, indicating a potentially
broader paradigm for crosstalk between AM signaling and receptor tyrosine kinases. Finally,
several studies have demonstrated that Epo and RA are essential regulators of epicardial-
derived growth factors (Chen et al., 1998, 2002; Wu et al., 1999; Stuckmann et al., 2003;
Merki et al., 2005). Although there are no data currently available that demonstrate a direct
relationship between AM and Epo, both of these peptides are strongly induced by hypoxia
through HIF-1alpha (Fandrey et al., 1994; Garayoa et al., 2000), which may indicate parallel
function. Finally, a limited number of studies have examined the relationship between AM
and RA (Minamino et al., 1995; Kubo et al., 1998). These studies have found that in
macrophages (Kubo et al., 1998) and vascular smooth muscle cells (Minamino et al., 1995),
RA induced Adm expression, indicating that Adm may be induced by RA in the epicardium
during cardiac development to regulate cardiomyocyte proliferation.
Future studies to elucidate these interactions are underway. For example, this Adm
overexpression model will be useful for understanding the importance of AM elevation
during disease, and with Cre-recombinase technology, we can begin to address in what
tissues and at what times AM elevation is advantageous. Additionally, the role of AM
during developmental processes of many organs, including the heart, lymphatic system, and
other organ systems, can be studied more thoroughly due to the viability of these animals.
Experimental Procedures
Animals
Admhi/hi mice were generated using standard gene targeting techniques, as described in
detail in (Li et al., 2013). Briefly, the targeting vector was designed to replace the
endogenous 3′UTR with a stabilizing cassette that increases the Adm mRNA half-life.
Additionally, loxP sites allow for the deletion of the stabilizing element and its replacement
by an 80 bp of AU/U-rich element of the mouse c-fos gene (ARE) (Fig. 6A). For
genotyping, a 3-primer, PCR-based strategy was used: primer 1: 5′-AACCTTAC
ACCTTGCTGAGACATTC-3′; primer 2: 5′-TTTATTAGGAAAGGACAGTGG
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GAGTG-3′; primer 3: 5′CCCACATT CGTGTCAAACGCTAC-3′. Primers 1 and 3
amplify a 760-bp wild-type allele, while primers 2 and 3 amplify a 600-bp targeted allele.
Mice used in these studies were either from a mixed genetic background or backcrossed to
the C57Bl6 strain for over nine generations. For all experiments, littermate animals were
used as controls.
To generate mice with reduced Adm expression either globally or in specific cells types,
Admhi/hi mice were crossed with the following previously characterized Cre mouse lines:
CMV-Cre (Schwenk et al., 1995), αMHC-Cre (Agah et al., 1997), Nkx2.5-Cre (Moses et
al., 2001), Fsp-Cre (Bhowmick et al., 2004), or Wt1GFPCre/+ (Zhou et al., 2008). The
recombined Admhi allele was designated Adm3′Δ. Heart weight to body weight (HW:BW)
ratios were assessed at 2 months of age. All studies were approved by the Institutional
Animal Care and Use Committee of UNC-CH.
Gene Expression Analysis
Adm gene expression was analyzed by qRT-PCR with the Mx3000P Real Time PCR System
from Stratagene. Primers for Adm amplification were 5′-GAGCGAAGCCCACATTCGT-3′
and 5′-GAAGCGGCATCCATTGCT-3′ and the probe sequence was 5′-FAM-
CTACCGCCAGAGCATGAACCAGGG-TAMRA-3′. Primers for Bnp amplification were
5′-CTGCTGGAGCTGATA AGAGA-3′ and 5′ -TGCCCAAAGCAGC TTGAGAT-3′
and the probe sequence was 5′-FAM-CTCAAGGCAGCACCCT CCGGG-TAMRA-3′.
Taqman Gene Expression Assays for Anp and GAPDH were purchased from Applied
Biosystems. Embryonic lung RNA from Ambion was used as calibrator. RNA was isolated
from mouse tissues with Trizol and subsequently DNaseI treated. The ΔΔCt method was
used to determine the relative levels of gene expression. Assays were repeated 3 times, each
time with triplicates.
Measurement of AM Peptide
Mouse AM was measured using a specific immunoradiometric assay kit (AM RIA,
Shionogi) with some modifications, as previously reported (Nishikimi et al., 2002, 2003a).
Plasma levels of AM were measured by a fluorescent immunoassay (Phoenix
Pharmaceuticals, FEK-010-08) following the manufacturer's protocol.
Adrenomedullin Staining
Paraffin embedded left ventricle sections were blocked for 1 hr in 5% normal donkey serum
at room temperature. Slides were then incubated with adrenomedullin antibody (Novus,
NBP1-19731) overnight at room temperature. Slides were washed with phosphate buffered
saline (PBS) before incubation with secondary antibodies for 2 hr at room temperature.
Cytokeratin Staining
Paraffin embedded tissues were subjected to three, 5-min rounds of antigen retrieval in 10
mM citric acid buffer/0.05% Tween 20. Slides were then blocked in 5% normal donkey
serum/0.1% Triton X at room temperature for 1 hr. Slides were incubated with diluted
cytokeratin primary antibody (Dako, Z0622) overnight at room temperature. After washing
slides with PBS, secondary antibody was applied for 2 hr at room temperature in the dark.
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Capillary Density and Cardiomyocyte Density Assay
Paraffin embedded heart sections were blocked in 1%BSA/0.2% triton X-100 in PBS for 1
hr, then incubated with Isolectin B4 fluorescein isothio-cyanate conjugate (Sigma L2895,
1:200), Rhodamine wheat germ agglutinin (Vector Laboratories, RL-1022, 1:1,000), and
1:1,000 DAPI in 1%BSA in PBS for 2.5 hr at room temperature, then washed in PBS and
rinsed with ddH2O.
Measurement of Mean Arterial Pressure
The mean arterial pressure (MAP) was assessed by the tail cuff method as previously
described (Krege et al., 1995). Briefly, mice were acclimated to the restraint apparatus for 2
days before data collection. For 3 days following the acclimation period, blood pressure data
were collected for each mouse. The data from the 3 days were then averaged together to
generate the MAP value.
BrdU Incorporation Assay
Timed matings were performed between Admhi/+ males and females. Two hours before the
dissection of the embryos, the pregnant female was injected with BrdU (0.1 mg/g of BW) by
means of tail vein injection. Embryos were carefully dissected and genotypes were
determined from DNA extracted from either the yolk sac or the tail. Frozen sections of the
heart were stained for BrdU using a diaminobenzidine (DAB)-based protocol.
Phospho-Histone H3 (Ser10) and Cardiac Troponin T Co-staining
Frozen E12.5 embryo heart sections were thawed overnight before antigen retrieval. Slides
were blocked in 10% normal goat serum in 0.05 M Tris buffer for 1 hr before applying
primary phospho-Histone H3 antibody (Cell Signaling, 9701) and cardiac troponin T
antibody (Thermo, MS-295-P) slides overnight at 4°C. Slides were washed with three
changes of 0.05 M Tris buffer before incubating with fluorescent secondary antibody for 2
hr at room temperature in the dark.
Cyclin B1 and Cyclin D1 Western blot
Hearts were dissected from postnatal day 1 pups and flash-frozen in liquid nitrogen. Protein
was isolated from wild-type and Admhi/hi hearts using standard procedures. Samples were
denatured and run on NuPage Bis-Tris gels and proteins were transferred to PVDF
membranes. Membranes were probed with cyclin B1 (Rockland, 100-401-152), cyclin D1
(Rockland, 100-401-153) and actin (Sigma, A4700) antibodies overnight at 4°C.
Membranes were incubated with secondary antibodies for 45minutes and imaged using a Li-
Cor Odyssey CLx. Integrated density was assessed using ImageJ software.
Proliferation of HL-1 Cells With AM Treatment
HL-1 cells are a cardiomyocyte cell line first developed and characterized by Claycomb et
al. in 1998 (Claycomb et al., 1998). When cultured in Claycomb media (Sigma, 51800C),
supplemented with norepinephrine and L-glutamine, these cells retain many properties of
cardiomyocytes, but, unlike isolated cardiomyocytes, will proliferate in culture (Claycomb
et al., 1998). For this experiment, HL-1 cells were plated in fibronectin/gelatin-coated 24-
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well dishes at a density of 50,000 cells per well in serum-free media. Cells were allowed to
adhere to the plates for 4 hr before treatment. At the time of treatment, the media was
removed from each well and replaced with serum-free media containing either tissue
culture-grade water as a vehicle control or 1nM AM (Phoenix Pharmaceuticals, 010-31).
Total cell numbers in each well were counted using a Countess Automated Cell Counter.
Each condition was performed in triplicate to allow for statistical analysis.
Statistics
Statistical analyses were performed with JMP software (SAS). One-way analysis of variance
was used to determine significance at P < 0.05. In all figures, error bars represent SEM.
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Abbreviations
AM adrenomedullin protein
Adm adrenomedullin gene
ANP atrial natriuretic peptide
BNP B-type natriuretic peptide
bGH bovine growth hormone
MAP mean arterial pressure
DAB diaminobenzidine
qRT-PCR quantitative RT-PCR
EIA enzyme immunoassay
HW:BW heart weight to body weight
HW:TL heart weight to tibia length
CW:BW chamber weight to body weight
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Key Findings
• Adrenomedullin is a secreted peptide with important functions during
embryonic development and cardiovascular disease.
• Adrenomedullin overexpression in mice was accomplished by gene targeted
insertion of a stabilizing element within the endogenous 3′ UTR.
• Admhi/hi mice show enlarged heart size due to cardiomyocyte hyperplasia during
development.
• Reversal of the cardiac hyperplasia is accomplished by Cre-mediated excision of
the genetic stabilizing element in epicardial cells.
• Epicardial-derived adrenomedullin drives myocyte proliferation during
development and thus represents a novel mitogenic factor potentially related to
mechanisms of cardiac repair after injury.
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Fig. 1.
Transcriptional and translational up-regulation of Adm. A: Quantitative RT-PCR analysis of Adm from wild-type and Admhi/hi
tissues (n = 3–10) at 4 months of age. B: Peptide levels of AM from 2- to 3-month-old wild-type and Admhi/hi lung and kidney
as determined by a radioimmunoassay (n = 5–6). C: Plasma levels of AM from 4-month-old wild-type and Admhi/hi animals
using a fluorescent immunoassay (n = 3). All values are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001
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Fig. 2.
AM expression is localized to the developing epicardium and up-regulated in Admhi/hi mice. Immunofluorescence of AM
peptide in heart sections of E13.5 embryos. A,C: Adm+/+ control mice. B,D: Admhi/hi mice. Images A,B were obtained with a
300 ms exposure, while images C and D were obtained with a 75 msec exposure. Boxes in A and B represent fields shown in
panels C and D, respectively. E: The amount of AM expressed in the epicardium was assessed from panels C and D by
measuring the integrated density of staining using Image J software. Data are expressed as arbitrary units (AU) of integrated
density. Colocalization of AM peptide and the epicardial marker, cytokeratin. F,H: Adrenomedullin staining. G,I: Cytokeratin
staining. The white boxes on panels F and G indicate the fields presented in panels H and I, respectively. Filled arrow heads on
panels F and H indicate areas of AM staining, while open arrow heads in panels G and I highlight areas positive for cytokeratin
staining. TR = trabecular zone; CZ = compact zone. Scale bars = 50 μM. All values are means ± SEM. **P < 0.01
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Fig. 3.
Admhi/hi mice have larger hearts that wild-type littermates. A: Gross appearance of hearts from 9-week-old male wild-type and
Admhi/hi mice. B: Heart weight to body weight (HW:BW) ratios were assessed at 2 months of age (n = 6–12). C: Heart weight
to tibia length (HW:TL) ratios were assessed at 2–4 months of age (n = 6). D: The ratio of left ventricle (LV), right ventricle
(RV), left atria (LA), and right atria (RA) to body weight was assessed at 2 months of age to obtain chamber weight to body
weight (CW:BW) ratios (n = 6–11). All values are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001
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Fig. 4.
Hearts of Admhi/hi mice are not hypertrophic. A: Representative heart sections were stained with hematoxylin and eosin (H&E).
The cardiomyocyte cross-sectional area was determined from 15 individual myocytes per animal (n = 3). B: Representative
heart sections were stained with isolectin (green), wheat germ agglutinin (WGA) (red), and DAPI (blue). We have also included
single channel views of the WGA and isolectin staining to aid in the visualization of the vascular and cellular density. C: Total
numbers of vessels and cardiomyocytes were quantitated from images at ×20 magnification (n = 3–8). Data shown here are
representative of two independent experiments conducted by separate researchers. D: Mean arterial pressure (MAP)
measurements assessed by tail cuff (n = 3–4). All values are means ± SEM.
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Fig. 5.
Enhanced proliferation of Admhi/hi hearts during embryonic development. A: Representative images of wild-type and Admhi/hi
hearts at embryonic day (E) 12.5 stained for BrdU. B: Quantitation of the total number of BrdU positive cells from wild-type
and Admhi/hi hearts throughout embryonic development normalized to the number of pixels in the image that were analyzed. C:
Representative images of wild-type and Admhi/hi hearts at E12.5 stained with phospho-Histone H3 (p-Histone H3) (green),
cardiac troponin T (cTnT) (red), and DAPI (blue). The white boxes on the ×4 (upper panels) and ×20 (middle panels) images
represent the areas magnified in the ×20 and ×40 (lower panels) images, respectively. Asterisks on ×40 images indicate
proliferating cardiomyocytes. The graph in the lower panel shows the number of phospho-Histone H3-positive cells per
cardiomyocyte, which was determined by assessing three ×20 magnification fields per animal (n = 3). D: Low-power images of
E15.5 wild-type and Admhi/hi hearts showing differences in heart size. Scale bar = 100 μm. E: Representative Western blot for
cyclin B1 and cyclin D1 normalized to actin. Each lane on the blot is loaded with protein lysates from individual postnatal day 1
pups. Differences in lane loading were accounted for by normalizing each cyclin band to the corresponding actin band for each
lane. These numbers were then normalized to a wild-type sample to compute the fold change. F: Proliferation of the HL-1
cardiomyocyte cell line with AM treatment. HL-1 cells were treated in serum-free media for 72 hours with either vehicle or 1
nM AM, before performing cell counts. Each condition was performed in triplicate. All values represent means ± SEM. *P <
0.05, **P < 0.01, ***P < 0.001
Wetzel-Strong et al. Page 24
Dev Dyn. Author manuscript; available in PMC 2015 February 01.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
Fig. 6.
Mice with excised bGH 3′UTR have normal-sized hearts. A: Gene targeting design indicating the location of loxP sites flanking
the bovine growth hormone (bGH) 3′UTR segment. B: Admhi/+ mice were bred to the CMV-Cre line to globally excise the bGH
3′UTR fragment from the Admhi allele. This new allele is designated as Adm3′Δ. After removing the Cre recombinase by means
of breeding, Adm expression was assessed by qRT-PCR (n = 5–6). C: At 2–3 months of age, the heart weight to body weight
(HW:BW) ratios of Adm3′Δ/3′Δ mice was compared with the HW:BW ratios of age-matched Admhi/hi and wild-type mice (n =
5–7). All values represent means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001
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Fig. 7.
Epicardial-derived AM contributes to cardiac hyperplasia of Admhi/hi mice. A: Admhi/hi mice were crossed with the Nkx2.5-Cre
mouse line to generate Admhi/hi animals with wild-type levels of Adm in cardiomyocytes. Heart weight to body weight
(HW:BW) ratios were assessed at 2 months of age (n = 4–8). B: Admhi/hi mice were crossed to the Fsp-Cre mouse line to
generate Admhi/hi mice with wild-type levels of Adm in fibroblasts. Heart weight to body weight (HW:BW) ratios were assessed
at 2 months of age (n = 4–10). C: Admhi/hi mice were crossed with the Wt1GFPCre/+ mouse line to generate Admhi/hi mice with
wild-type levels of Adm in the epicardium. At 2 months of age, heart weight to body weight (HW:BW) ratios were assessed (n =
3–6). D: Adjacent left ventricle sections from wild-type, Admhi/hi, and Wt1GFPCre/+:Adm3′Δ/3′Δ mice were stained with
adrenomedullin (left panels) and the epicardial marker, cytokeratin (right panels). Adrenomedullin and cytokeratin images were
acquired with a 130 ms exposure for all images. Images were acquired at ×20 magnification and the scale bar represents 50 μm.
E: The amount of AM expressed in the epicardium was assessed from the images in panel D by measuring the integrated density
using Image J software. The data are presented as arbitrary units (AU) of integrated density. F: RNA extracted from 2-month-
old left ventricle samples was used to assess the relative expression levels of Adm by qRT-PCR. All values represent means ±
SEM. *P < 0.05, **P < 0.01, ***P < 0.001
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